Cystatin C-based eGFR predicts cardiovascular disease in patients with overweight/obesity and hyperglycemia.
Keita SuzukiHiromasa TsujiguchiAkinori HaraHiroyuki NakamuraKazuhiko KotaniMitsuhiko NodaHajime YamakageNoriko Satoh-AsaharaToshinari TakamuraPublished in: Obesity science & practice (2022)
UMIN000000559.